These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 21317681)
21. [Safety of daptomycin in patients with renal impairment]. Azanza JR; Quetglas EG Med Clin (Barc); 2010 Dec; 135 Suppl 3():55-9. PubMed ID: 21477705 [TBL] [Abstract][Full Text] [Related]
22. Evaluation of the safety, tolerability, and pharmacokinetics of a single bolus injection of daptomycin in healthy Japanese subjects. Aoki I; Ishikawa K; Wakana A; Aso M; Yoshinari T J Infect Chemother; 2015 Mar; 21(3):170-5. PubMed ID: 25572140 [TBL] [Abstract][Full Text] [Related]
23. Variability of pharmacokinetic parameters in patients receiving different dosages of daptomycin: is therapeutic drug monitoring necessary? Falcone M; Russo A; Cassetta MI; Lappa A; Tritapepe L; d'Ettorre G; Fallani S; Novelli A; Venditti M J Infect Chemother; 2013 Aug; 19(4):732-9. PubMed ID: 23361566 [TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and safety of multiple intravenous doses of daptomycin in a Taiwanese adult population. Liang SH; Sheng WH; Huang YT; Wu FL; Chang SC Chemotherapy; 2009; 55(2):91-6. PubMed ID: 19145078 [TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics and tolerability of single-dose daptomycin in young infants. Cohen-Wolkowiez M; Watt KM; Hornik CP; Benjamin DK; Smith PB Pediatr Infect Dis J; 2012 Sep; 31(9):935-7. PubMed ID: 22627869 [TBL] [Abstract][Full Text] [Related]
32. Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30 min infusion or 2 min injection. Chakraborty A; Roy S; Loeffler J; Chaves RL J Antimicrob Chemother; 2009 Jul; 64(1):151-8. PubMed ID: 19389714 [TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and pharmacodynamics of daptomycin in a clinical setting. Tsukada H; Tsuji Y; Yamashina T; Tsuruta M; Hiraki Y; Tsuruyama M; Ogami C; Kawasuji H; Sakamaki I; Yamamoto Y J Infect Chemother; 2020 Feb; 26(2):230-235. PubMed ID: 31735632 [TBL] [Abstract][Full Text] [Related]
34. Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects. Wong SL; Barriere SL; Kitt MM; Goldberg MR J Antimicrob Chemother; 2008 Oct; 62(4):780-3. PubMed ID: 18586659 [TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of azithromycin after single- and multiple-doses in children. Stevens RC; Reed MD; Shenep JL; Baker DK; Foulds G; Luke DR; Blumer JL; Rodman JH Pharmacotherapy; 1997; 17(5):874-80. PubMed ID: 9324176 [TBL] [Abstract][Full Text] [Related]
37. Characterization of the pharmacokinetic disposition of levofloxacin in stallions after intravenous and intramuscular administration. Goudah A; Abo El-Sooud K; Shim JH; Shin HC; Abd El-Aty AM J Vet Pharmacol Ther; 2008 Oct; 31(5):399-405. PubMed ID: 19000258 [TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of high-dose daptomycin (>6 mg/kg) for complicated bone and joint infections and implant-associated infections caused by Gram-positive bacteria. Perrottet N; Steinrücken J; Chan M; Pannatier A; Borens O; Yusuf E; Trampuz A Int J Antimicrob Agents; 2015 Oct; 46(4):480-2. PubMed ID: 26235888 [No Abstract] [Full Text] [Related]
39. Daptomycin Pharmacokinetics and Pharmacodynamics in Patients on Methadone Substitution Therapy. De Gregori S; De Silvestri A; Molinaro MD; Monzillo V; Biscarini S; Colaneri M; Gallazzi I; Bartoli A; Bruno R; Seminari E Eur J Drug Metab Pharmacokinet; 2021 Jul; 46(4):547-554. PubMed ID: 34231117 [TBL] [Abstract][Full Text] [Related]
40. A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria. Katz DE; Lindfield KC; Steenbergen JN; Benziger DP; Blackerby KJ; Knapp AG; Martone WJ Int J Clin Pract; 2008 Sep; 62(9):1455-64. PubMed ID: 18662172 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]